Track Medicenna Therapeutics Corp. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Medicenna Therapeutics Corp. MDNA.TO · Stock Open Medicenna Therapeutics Corp. in new tab

0.4500 CAD
EPS
-0.22
P/B
25.00
ROE
-227.57
Beta
2.10
Target Price
3.20 CAD
Loading chart...
Key Metrics
Earnings dateNov. 16, 2026
EPS-0.22
Book Value0.02
Price to Book25.00
Debt/Equity6.22
% Insiders18.822%
Estimates
Forward P/E-1.96
Forward EPS-0.23
Target Mean Price3.20

DCF valuation

Model fair value for Medicenna Therapeutics Corp. (MDNA.TO)
Result
Sign in to run the valuation for MDNA.TO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 3.20 CAD (low 1.60, high 4.00)
Low 1.60
Mean 3.20
High 4.00
Price 0.4500
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Medicenna Therapeutics Corp. Logo Medicenna Therapeutics Corp. Analysis (MDNA.TO)

Canada Health Care Official Website Stock

Is Medicenna Therapeutics Corp. a good investment? Medicenna Therapeutics Corp. (MDNA.TO) is currently trading at 0.4500 CAD. Market analysts have a consensus price target of 3.20 CAD. This suggests a potential upside from current levels.

Earnings Schedule: Medicenna Therapeutics Corp. is expected to release its next earnings report on Nov. 16, 2026. The market consensus estimate for Forward EPS is -0.23.

Investor FAQ

Does Medicenna Therapeutics Corp. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Medicenna Therapeutics Corp.?

Medicenna Therapeutics Corp. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 16, 2026. The company currently has a trailing EPS of -0.22.

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Exchange Ticker
NCM (Australia) MDNA
TOR (Canada) MDNA.TO
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion